Publications by authors named "Maya Aslam"
The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, and T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort of 24 participants at time points ranging from 27 to 910 days after acute SARS-CoV-2 infection using the radiopharmaceutical agent [F]F-AraG, a selective tracer that allows for anatomical quantitation of activated T lymphocytes.
View Article and Find Full Text PDFImproved imaging modalities are needed to accurately stage patients with muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Imaging with small-molecule ligands or inhibitors of fibroblast activation protein (FAP) is a promising modality that has demonstrated initial efficacy across a broad range of tumors. We present our experience with the novel FAP-peptide binder Ga-FAP-2286 in patients with MIBC.
View Article and Find Full Text PDFBackground: Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [Lu]-prostate-specific membrane antigen (PSMA)-617 (Lu-PSMA-617) followed by maintenance pembrolizumab was safe and could induce durable clinical benefit.
Methods: We did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA).
The etiologic mechanisms of post-acute medical morbidities and unexplained symptoms (Long COVID) following SARS-CoV-2 infection are incompletely understood. There is growing evidence that viral persistence and immune dysregulation may play a major role. We performed whole-body positron emission tomography (PET) imaging in a cohort of 24 participants at time points ranging from 27 to 910 days following acute SARS-CoV-2 infection using a novel radiopharmaceutical agent, [F]F-AraG, a highly selective tracer that allows for anatomical quantitation of activated T lymphocytes.
View Article and Find Full Text PDFArticle Synopsis
- HIV infection has a long-lived viral reservoir in persistently infected cells, which makes achieving a functional cure difficult; non-invasive methods to study this issue are critical.
- ImmunoPET imaging, using a specific radiolabeled antibody, has been assessed as a way to visualize and evaluate HIV reservoirs and viral activity in infected individuals compared to uninfected controls.
- Results show increased uptake of the imaging agent in tissues of HIV-infected individuals, positively correlating with direct measurements of HIV protein, suggesting a potential method for non-invasive monitoring of HIV persistence and opening avenues for similar applications in other diseases.
The purpose of this prospective study was to determine the correct localization rate (CLR) of F-fluorocholine PET for the detection of parathyroid adenomas in comparison to Tc-sestamibi imaging. This was a single-arm prospective trial. Ninety-eight patients with biochemical evidence of primary hyperparathyroidism were imaged before parathyroidectomy using F-fluorocholine PET/MRI.
View Article and Find Full Text PDFArticle Synopsis
- Prostate-specific membrane antigen (PSMA) shows potential as a diagnostic tool for aggressive thyroid cancer due to its expression in the cancer's microvasculature.
- In a study involving 11 thyroid cancer patients, PSMA PET/MRI detected 65.1% of lesions compared to a 95.3% detection rate for the traditional FDG PET scan, indicating lower effectiveness for PSMA.
- While PSMA uptake varied among patients and was not predictable based on cancer subtype, 8 out of 11 participants might qualify for future PSMA radioligand therapy based on existing prostate cancer guidelines.